We are a unique partnership of senior advisors with proven expertise in the translation of precision medicine and health tools into clinical practice and patient impact.
Richard Barker is a senior leader in the global life sciences sector. His professional interests focus on innovation and translation in precision medicine and precision health, drawing on his 30-year career in senior roles in biopharmaceuticals (Director General of the ABPI, UK and NED at Celgene, US), diagnostics (CEO of Chiron Diagnostics, US) and medical informatics (Global General Manager of IBM Healthcare, UK). He chaired the Population Health section of the recent UK All-Party Parliamentary Group on Health Longevity.
His other positions include Co-Founder of two early-stage businesses, Metadvice (healthcare AI) and Innohealth (Asia/Europe biotech licensing), Chairman of the Health Innovation Network, UK and a Non-Executive Director for the Image Analysis Group, UK. He also holds honorary faculty positions at Oxford University, UK and Kings College London, UK.
Richard has published two Oxford University Press books: ‘2030—the future of medicine’ and ‘Bioscience—lost in translation?’ as well as numerous academic papers.
Prof. Richard Barker
Founder & CEO
Olga Shvarova is a Technology Transfer expert with extensive experience in commercialisation strategy, IP protection strategy and management, technology appraisal, and innovation policy, and has held a number of senior posts in med-tech, M&A, corporate finance and private equity firms.
Her other positions include: Senior Consultant at Oxentia, Associate Partner at Ruffena Capital, Senior Consultant at McGrigor Group. Olga also works with private clients on the ad hoc basis. She is also a Technology Transfer and Commercialisation Expert within the Centre of Competence on Technology Transfer within the European Commission’s Joint Research Centre and an Advisor for Asia-Pacific Economic Cooperation (APEC) Centre for Technology Transfer (APCTT).
Olga’s publications within the medical sector include: Health Technology Assessment of Aging Therapies. Shvarova O.Y. (2019) Jul 31, 2019. In: Gu D., Dupre M. (eds) Encyclopaedia of Gerontology and Population Aging. Springer, Cham.
Dr Olga Shvarova
COO
Alan Roth is an experienced management consultant working within health sciences with a focus on basic research, investment management/capital markets, strategic consultancy and executive operations. His career spanned as New Lead Discovery Department at Merck, McKinsey, Commerzbank Asset Management ($140bn AUM) in London and Frankfurt, and Chiral Quest, a life sciences company in the area of chiral pharmaceuticals.
His current positions include: Entrepreneur in Residence at the University of Oxford, Director at Fitzroy Partners, a Guest Professor at the University of Cologne (Germany), the University of Tianjin (China), and the US Military Academy, West Point (USA).
Dr Alan D Roth
Non-Executive Director
Nick Housby is a specialist in microbial genetics, genomics and biotechnology with experience in technology transfer, new business incubation, and start-up/spinoff creation (Oxagen (Human Genetics, 2003) Novolytics (antimicrobial therapeutics, 2010), BioMimox (peptide aptamers, 2014), Arcamis (business consulting, 2010). He also led the creation of the Molecular Diagnostics Centre within the John Radcliffe Hospital, Oxford and the Oxford Genomics Medicine Centre.
His current positions include: CEO of Accunea Ltd, a medical device company with real-time diagnostic monitoring products for patients with AKI, a Strategic and Commercial Advisor for Capital Cell, a life sciences crowdfunding organisation based in the UK and Spain.
Nick is a current member of the Diagnostics Advisory Council in Oxfordshire.
Dr Nick Housby
Non-Executive Director
Andrew Krentz is an academic clinician and researcher focused on metabolic, endocrine and cardiovascular disorders.
His current positions include: Visiting Professor, Institute of Cardiovascular & Metabolic Research, University of Reading, UK; Academic Fellow, Centre for the Advancement of Sustainable Medical Innovation (CASMI), UK; Senior Research Fellow, ProSciento, San Diego, USA; Editor-in-Chief Cardiovascular Endocrinology & Metabolism, London, UK; Consultant Physician, London Diabetes Clinic, UK; Clinical Instructor, University of California San Diego, USA.
He is a National Council Member of the Royal Society of Medicine Section of Lipids, Metabolism & Vascular Risk, UK and an Elected Member of the Medical Scientific & Research Committee of the cholesterol charity, Heart UK. He is accredited as a clinical specialist by the European Society for Hypertension. In 2019, Andrew was awarded honorary Fellowship of the Faculty of Pharmaceutical Medicine in recognition of outstanding contributions to pharmaceutical medicine.
Andrew’s textbook publications include: Insulin Resistance: A Clinical Handbook (2002); The Metabolic Syndrome & Cardiovascular Disease (2007); Drug Treatment of Type 2 Diabetes (2012); Translational Research Methods for Diabetes, Obesity & Cardiometabolic Drug Development: A Focus on Early Phase Clinical Studies (2015).
Dr Andrew Krentz
Clinical & Pharmaceutical Medicine
Paul Simms is an industry influencer, author and serial entrepreneur. Paul started as a Chairman of Eyeforpharma in 2003 and grew the company into the pharmaceutical industry’s most influential convener of leadership meetings and talent, leading to acquisition by Reuters in October 2019.
His current positions include: Advisor to Humany.co and a few small disruptive companies at pharma’s cutting edge. Paul regularly hosts CEOs and disruptors in equal measure across online and physical events in Barcelona, Philadelphia, Tokyo, Berlin, London, Miami, Singapore, Shanghai and Sydney and has possibly the largest contact book in the pharmaceutical industry, covering all major companies at C-level. Paul is also CEO of Lydia Lets Ltd and Lydia Homes Ltd.
Paul writes regularly for various media channels.
Paul Simms
Pharmaceutical Industry
Charles Alessi is a senior-level professional in both primary and secondary care as well as PCTs and Health Authorities specialising in health and social care reforms. He also has experience of military medicine until recently acting as Director of Medicine and Clinical Governance for the British Armed Forces in Germany.
His other positions include: a Senior Advisor for Public Health England where he leads dementia and risk reduction initiatives and is a Director of Antibiotic Prescribing within Antimicrobial Resistance Initiative. He is also a Visiting Scholar at the world health innovation network at the Odette School of Business, University of Windsor, Ontario Canada.
Dr Charles Alessi
Public Healthcare Systems
Dr Elin Haf Davies has combined her career in paediatric health and clinical and academic drug trials. She began her career as a Paediatric Nurse at Great Ormond Street Children’s Hospital in London, moving after 12 years to research in the development of age-appropriate and disease-specific biomarkers and clinical endpoints in neurometabolics.
Her current positions include: a CEO at Aparito, UK, the Chair at Metabolic Support, UK Research Fellow at the Centre for Health Economics & Medicines Evaluation at Bangor University, UK, and Associate Fellow Centre for the Advancement of Sustainable Medical Innovation (CASMI), UK.
Elin has been nominated in Tech50 women winners within Tech50 shortlist (2017).
Dr Elin Haf Davies
Regulatory Affairs
Tina Woods is an author and an entrepreneur working in both private and public sectors to accelerate innovation and transform health with sustainable impact at scale.
Her current positions include: a CEO and Founder of Collider Health, UK a health innovation catalyst, a CEO & Founder of Collider Science, UK a social enterprise aimed at young scientists, and a CEO and Co-founder of Longevity International, UK which works with the secretariat for the All-Party Parliamentary Group for Longevity. Tina also works with national AHSN AI Network to support an AI and data-driven tech ecosystem for the NHS and the new NHSX team on a number of activities related to the development of open innovation including the recently announced NHSX AI Lab and with the Healthy Ageing Industrial Strategy Challenge Fund with UK Research & Innovation.
Tina writes regularly for Forbes, D/sruption and other media channels and published a book ‘Live Longer with AI: How artificial intelligence is helping us extend our healthspans and live better too' (2020).
Tina Woods
Healthy Ageing & Data Access
Professor Scott is a Professor Emeritus of Medicine and Cardiovascular Medicine at Imperial College London, UK.
He qualified in medicine at the Royal London Hospital in 1971, was a Chief of Academic Medicine and of NHS clinical service, and a Chief of Cardiology and Head of Molecular Medicine at The Royal Postgraduate Medical School, Hammersmith Hospital, UK. He was founder and first Head of the Institute of Genetics and Genomics and founder of the Bioinformatics Centre at Imperial College London.
He is a Fellow of The Royal College of Physicians London, a founder member of the Academy of Medical Sciences, member of the European Molecular Biology Organisation, a Chartered Biologist and Fellow of the Institute of Biology. He is a Fellow of the Royal Society (The UK National Academy of Sciences). He received prizes from The Royal College of Physicians London, Glaxo Smith Kline, and Bristol Myers Squibb.
James authored over 240 published chapters, articles and abstracts and is most recognized for his discovery of common genetic variation causing dyslipidaemia, heart disease and obesity, and the novel mechanism of nucleic acid editing, a process concerned with cholesterol transport, antibody formation, protection against HIV and stem cell programming.
Prof. James Scott
Gene Therapy
Bob Hariri is a surgeon, biomedical scientist and highly successful serial entrepreneur in two technology sectors: biomedicine and aerospace. He has pioneered the use of stem cells to treat a range of life-threatening diseases and has made transformative contributions in the field of tissue engineering.
His current positions include The Chairman, Founder, and CSO of Celgene Cellular Therapeutics, US, Academic Neurosurgeon at Cornell, US, a Non-executive Director of Myos Corporation, US and Provista Diagnostics, US, an Adjunct Associate Professor of Pathology at the Mount Sinai School of Medicine, US, a member of the Board of Visitors of the Columbia University School of Engineering & Applied Sciences and the Science & Technology Council of the College of Physicians and Surgeons, and of the scientific advisory board for the Archon X PRIZE for Genomics.
He is a Trustee of the Liberty Science Center and a Commissioner of Cancer Research by NJ Governor Christie, a member of the Board of Trustees of the J. Craig Venter Institute and was a recipient of the Thomas Alva Edison Award (2007, 2011), and The Fred J. Epstein Lifetime Achievement Award.
Bob authored over 90 issued and pending patents, over 100 published chapters, articles and abstracts and is most recognized for his discovery of placenta-derived pluripotent stem cells.
Dr Bob Hariri
Cell Therapy & Tissue Engineering
Worldwide network of experts
We also have access to worldwide experts in key sectors:
Structural Genomics
Clinical Medicine
Drug Discovery
Oncology
International Compliance and Regulation
Cell & Gene Therapy
Health Economics
Pharmacoeconomics
Molecular Diagnostics
Clinical Genetics
Public Health
Clinical Education and Training in Precision Medicine
Technology Transfer
Clinical Trials Design in Precision Medicine
